Ali Delbakhsh
Cardiovascular Disease · El Cajon, CANPI 1154365872
Payments from drug & device makers
Across 171 payments — averaging $24.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$638
- Johnson & Johnson$579
- Novartis$417
- Boston Scientific$298
- AstraZeneca$240
- E.r. Squibb & Sons, L.L.C.$236
- plus $2K from 23 others
What the payments were for
- Food & beverage$4,18999%
- Education$261%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 22 | $638 |
| Johnson & Johnson | 37 | $579 |
| Novartis | 20 | $417 |
| Boston Scientific | 12 | $298 |
| AstraZeneca | 9 | $240 |
| E.r. Squibb & Sons, L.L.C. | 7 | $236 |
| Bayer | 2 | $229 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $204 |
| Novo Nordisk | 3 | $166 |
| Astellas Pharma US Inc | 2 | $164 |
| Amgen | 8 | $159 |
| Sanofi-aventis U.S. LLC | 9 | $133 |
| Amarin Pharma, Inc. | 6 | $128 |
| Esperion Therapeutics, Inc. | 2 | $128 |
| Medtronic(2 entities) | 2 | $58 |
| Actelion Pharmaceuticals US, Inc. | 4 | $51 |
| Regeneron Healthcare Solutions, Inc. | 3 | $49 |
| Abbott | 2 | $46 |
| Lundbeck LLC | 2 | $43 |
| Abiomed | 2 | $43 |
| Boehringer Ingelheim | 2 | $40 |
| Gilead | 2 | $37 |
| Scpharmaceuticals Inc. | 1 | $26 |
| Lexicon Pharmaceuticals, Inc. | 1 | $19 |
| Baxter Healthcare | 1 | $19 |
| Lilly USA, LLC | 1 | $18 |
| Merck | 1 | $16 |
| Getinge USA Sales, LLC | 1 | $15 |
| Philips North America LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,215 in reported general payments places this provider in the 55th percentile of 2,184 cardiovascular disease providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 226 | $256,188 |
| EntrestoSacubitril/Valsartan | 88 | $97,957 |
| XareltoRivaroxaban | 31 | $29,543 |
| BrilintaTicagrelor | 29 | $20,787 |
| MultaqDronedarone Hcl | 12 | $15,185 |
| Repatha SureclickEvolocumab | 11 | $14,990 |
| Repatha SyringeEvolocumab | 12 | $8,271 |
| Metoprolol Succinate | 496 | $6,235 |
| Amiodarone Hcl | 120 | $4,228 |
| Potassium Chloride | 156 | $3,496 |
| Digoxin | 101 | $3,045 |
| Atorvastatin Calcium | 258 | $2,630 |
| Carvedilol | 256 | $2,177 |
| Bumetanide | 75 | $2,169 |
| Losartan Potassium | 259 | $2,108 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $638 | $256,188226 claims |
| NovartisEntresto | $417 | $97,95788 claims |
| Johnson & JohnsonXarelto | $579 | $29,54331 claims |
| AstraZenecaBrilinta | $240 | $20,78729 claims |
| Sanofi-aventis U.S. LLCMultaq | $133 | $15,18512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in El Cajon
- Ted LoveHillsborough$102.8M
- Matthew BudoffTorrance$11.3M
- Lori DanielsSan Diego$10.2M
- Paul KurthSanta Barbara$6.1M
- Michael BlumSan Francisco$5.5M
- Tony ChouSan Francisco$5.2M
- Jason RogersSacramento$5.1M
- Yu-Ping WangStanford$3.8M
- Yogesh PaliwalPomona$3.3M
- Farhad RafiiWest Hills$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.